Pretreatment ANC, on-treatment ANC, and dose of G-CSF in patients with SCN. Panels A-D show data for SCN Group 6, while panel E shows data for SCN Group 5 (Table 1). (A) Histograms of mean ANC values prior to treatment (red bars), and mean ANC values during the 6-18 month follow-up period (blue bars), shown on a log₂ scale. A vertical reference line is shown at 1500 cells/μL, corresponding to the therapeutic target. (B) Box plot of mean ANC values during the 6-18 month follow-up minus pretreatment mean ANC values, displaying the median value, inter-quartile range, 10th and 90th percentiles, and outliers (plus signs). Notches show 95% confidence intervals for the median. (C) Box plots of G-CSF dose values (μg/kg/d), by follow-up period. Box plots are constructed as described for panel B. Two hundred eleven patients contributed 2,440 G-CSF dose values over time; all values for each patient are shown. Starting dose corresponds to 0-3 days of follow-up; 6 m, to between 3 days and 8 months; 1 y, to between 9 and 14 months; 1.5 y, to between 15 and 20 months; 2 y, to between 21 and 26 months; and after 2 y, to between 27 months and 12.44 years. (D) Histogram of G-CSF dose (μg/kg/d) for each patient at or closest to 6 months. The right-most bar represents 4 patients with dose values of 120, 128, 189, and 576 μg/kg/d. (E) Dose of G-CSF at 6 months, and average ANC response over the subsequent year. Dose of G-CSF is plotted on the log₂ scale. Curve plots the mean value. Shaded area corresponds to 95% point-wise confidence limits. The nonparametric regression incorporated precision weights equal to the number of CBC values available for each patient during the 6- to 18-month follow-up period.